Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904526 · ClinicalTrials.gov registry record · Phase 2
PK/PD Comparison of Guanfacine ER and IR
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01904526 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT01904526, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.
Interventions
- DRUG Guanfacine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01904526
The ClinicalTrials.gov registry entry for NCT01904526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guanfacine is the first listed.
NCT01904526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01904526 about?
NCT01904526 is a clinical study titled "PK/PD Comparison of Guanfacine ER and IR". Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.
What is the current status of trial NCT01904526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2013-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01904526?
The interventions under investigation include: Guanfacine (DRUG).
Who is sponsoring clinical trial NCT01904526?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.